In conclusion, the GNAS mutation serves as a valuable molecular marker in distinguishing IPMN and its inclusion in testing panels enhances the accuracy of IPMN diagnosis [78]. This evidence concerns the gene GNAS and pancreatic intraductal papillary-mucinous neoplasm.